Inventor · disambiguated record
Chao Qi
Also filed as: QI CHAO
20 granted patents·26 pending applications·75 citations·filing 2012–2025
92Inventor score
Files withINCYTE CORP31TENCENT TECH SHENZHEN CO LTD3MIANYANG BOE OPTOELECTRONICS TECH CO LTD2SYNNOVATION THERAPEUTICS INC2Baidu online network technology beijing co ltd1
Top patents by PatentIndex Score
46 records- 0198US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 0298US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 0396US11607416B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Mar 21, 2023·7 cites·52 claims
- 0494US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 0591US12083124B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2023·Granted Sep 10, 2024·1 cites·30 claims
- 0689US11161850B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 2, 2021·5 cites·12 claims
- 0782US11111247B2Pyrazolopyrimidine compounds and uses thereofINCYTE CORP·Filed 2019·Granted Sep 7, 2021·1 cites·48 claims
- 0880US11939328B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Mar 26, 2024·0 cites·35 claims
- 0980US2023357255A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 1080US2025057852A1Bicyclic heterocycles as fgfr inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1179US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 1276US10442712B2Membrane bioreactor for strengthening membrane fouling control and method thereofNANJING UNIVERSITY OF TECHNOLOGY·Filed 2017·Granted Oct 15, 2019·2 cites·7 claims
- 1376US2025041310A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1475US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 1575US2024360140A1Fused pyrazine derivatives as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1675US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 1774US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 1869US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 1967US11999740B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jun 4, 2024·0 cites·36 claims
- 2065US12441731B2Pyrazolopyrimidine compounds and uses thereofINCYTE CORP·Filed 2021·Granted Oct 14, 2025·0 cites·54 claims
- 2164US12466822B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Nov 11, 2025·0 cites·28 claims
- 2262US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 2362US11086512B2Information processing apparatus of displaying text with semantic segments thereof marked and determining and displaying candidate operations matching user intent corresponding to the text, information processing method thereof, and computer-readable storage mediumTENCENT TECH SHENZHEN CO LTD·Filed 2018·Granted Aug 10, 2021·1 cites·23 claims
- 2462US2025346603A1Tricyclic compounds as pi3kalpha inhibitorsPIKAVATION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2561US2021205311A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 2661US2025270213A1PI3Ka INHIBITORSSYNNOVATION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2761US2025171444A1PI3Ka INHIBITORSSYNNOVATION THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2860US2019292188A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2019·Application pending·0 cites
- 2958US12077539B2Imidazole and triazole KRAS inhibitorsINCYTE CORP·Filed 2022·Granted Sep 3, 2024·0 cites·42 claims
- 3058US2022233529A1Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodiesINCYTE CORP·Filed 2021·Application pending·0 cites
- 3158US2021269434A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2021·Application pending·0 cites
- 3257US12441742B2Naphthyridine compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 3357US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 3455US2018179202A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 3555US2024112405A1Data processing method, electronic device, and stroage mediumLENOVO BEIJING LTD·Filed 2023·Application pending·0 cites
- 3653US2021355121A1Fused tricyclic kras inhibitorsINCYTE CORP·Filed 2021·Application pending·0 cites
- 3751US11591329B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Feb 28, 2023·0 cites·58 claims
- 3851US2022231103A1Display substrate and method for manufacturing same, and display deviceMIANYANG BOE OPTOELECTRONICS TECH CO LTD·Filed 2021·Application pending·0 cites
- 3948US2023162963A1Efficient and stable secondary ion extraction apparatusINST OF GEOLOGY CHINESE ACADEMY OF GEOLOGICAL SCIENCES·Filed 2022·Application pending·0 cites
- 4044US11859262B2Large-sized high-Nb superalloy ingot and smelting process thereofGAONA AERO MAT CO LTD·Filed 2020·Granted Jan 2, 2024·0 cites·6 claims
- 4144US2024324118A1Flexible Display Module and Display DeviceMIANYANG BOE OPTOELECTRONICS TECH CO LTD·Filed 2022·Application pending·0 cites
- 4243US2015302056A1Method, system, and storage medium for information searchTENCENT TECH SHENZHEN CO LTD·Filed 2013·Application pending·0 cites
- 4336US10423648B2Method, system, and computer readable medium for interest tag recommendationTENCENT TECH SHENZHEN CO LTD·Filed 2015·Granted Sep 24, 2019·0 cites·20 claims
- 4436US2015188883A1Method and service system for implementing domain name registration and resolution based on domain name groupCOMPUTER NETWORK INF CT CAS·Filed 2012·Application pending·0 cites
- 4535US2016379106A1Human-computer intelligence chatting method and device based on artificial intelligenceBaidu online network technology beijing co ltd·Filed 2015·Application pending·0 cites
- 4632US2016136241A1Methods of preparing and using sericin hydrogelUNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chao Qi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →